申请人:Dewdney Nolan James
公开号:US20090186898A1
公开(公告)日:2009-07-23
This application discloses novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives according to Formulae I-VI:
wherein R, R′, R″, Q, X, and Y are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-VI and at least one carrier, diluent or excipient.
本申请披露了根据公式I-VI定义的新型咪唑[1,2-a]吡啶和咪唑[1,2-b]吡嗪衍生物,其中R、R'、R"、Q、X和Y如本文所述,可抑制Btk。本文披露的化合物有助于调节Btk的活性,并治疗与过度Btk活性相关的疾病。这些化合物还有助于治疗与异常B细胞增殖相关的炎症和自身免疫性疾病,如类风湿性关节炎。本文还披露了含有公式I-VI化合物和至少一种载体、稀释剂或赋形剂的组合物。